Novartis is preparing to file for approval of its radioligand therapy Lutathera as a first-line treatment for people with rare neuroendocrine tumours after it showed a benefit in a phase 3 trial.

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

Novartis Oncology. "With Lutathera we can build on this legacy by expanding the global reach of this novel, differentiated treatment approach and work to maximise Advanced Accelerator Applications ...

Novartis currently markets Lutathera (lutetium Lu 177 dotatate), an approved peptide receptor radionuclide therapy (PRRT) for SSTR-positive GEP-NETs. Sanofi has also entered the space, having ...

FDA granted an accelerated approval for Vanrafia for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Vanrafia can be ...

In addition to the sale, Novartis and Siemens Healthineers will collaborate to enhance the supply of nuclear isotopes used in radiopharma drugs like Lutathera. Price Action: NVS stock is up 0.47% ...

Over the course of two years, Williams has been treated four times with Lutathera, which is targeted internal radiotherapy. “I go to a room in King’s College hospital and people in hazmat ...

The research at MURR led to the development of lutetium-177, which is now the active ingredient in radiopharmaceuticals, Pluvicto and Lutathera. Both treatments, made by Novartis, are successfully ...

During an earnings call, the firm reported strong sales for Pluvicto and other precision medicines and elaborated on its US manufacturing plans.

Every jurisdiction other than PEI and the territories already covers Lutathera for neuroendocrine cancer, according to Novartis, which makes both drugs. London Health Sciences Centre was the first ...